Voltage-gated Potassium Channels as Therapeutic Drug Targets
By Heike Wulff, N. Castle, L. Pardo. Nature reviews. Drug discovery, 2009
758 citations recorded by the source corpus.
The human genome encodes 40 voltage-gated K+ channels (KV), which are involved in diverse physiological processes ranging from repolarization of neuronal and cardiac action potentials, to regulating Ca2+ signalling and cell volume, to driving cellular proliferation and migration. KV channels offer tremendous opportunities for the development of new drugs to treat cancer, autoimmune diseases and metabolic, neurological and cardiovascular disorders. This Review discusses pharmacological strategies for targeting KV channels with venom peptides, antibodies and small molecules, and highlights recent progress in the preclinical and clinical development of drugs targeting the KV1 subfamily, the KV7 subfamily (also known as KCNQ), KV10.1 (also known as EAG1 and KCNH1) and KV11.1 (also known as HERG and KCNH2) channels.
Subfields: Cardiology and Cardiovascular Medicine, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/7bfcc6a0e894d38b02a9308f061c7d4c4d330640
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Structure-based drug discovery and protein targets in the CNS. (2011, background): “These have provided a framework within which the different modes and natures of modulating the activity of these channels can be discussed (Wulff et al., 2009).”